Lack of evidence into paediatric cannabinoid use
The researchers found the strongest evidence of cannabinoid benefit in chemotherapy-induced nausea and vomiting, and in epilepsy
More than half of all American states now have provision for the legal prescription of cannabinoids for medical use, including to children. But there is limited evidence on their efficacy in paediatric populations.
To explore, researchers carried out a systematic review and meta-analysis of 22 studies including 795 child and adolescent patients treated with cannabinoids.
The researchers found the strongest evidence of a benefit in chemotherapy-induced nausea and vomiting, and in epilepsy. However, there was not enough evidence to support use in any other indications including spasticity, neuropathic pain, post-traumatic stress disorder and Tourette’s syndrome.
Noting the often poor methodological quality of the available studies in Pediatrics (November 2017), the team said that further research was needed given the increasing accessibility of medical cannabinoids and likelihood of adverse effects.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20204048
Recommended from Pharmaceutical Press
Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.£22.00
The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.£25.00
Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.£38.00
This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.£48.00
Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.£38.00